Core Viewpoint - Scilex Holding Company has appointed Kasowitz LLP and its founding partner Marc Kasowitz as its litigation and intellectual property counsel to enhance its legal capabilities in protecting and advancing its proprietary pharmaceutical assets and development pipeline [1][2][3]. Company Overview - Scilex is focused on acquiring, developing, and commercializing non-opioid pain management products for treating acute and chronic pain, as well as neurodegenerative and cardiometabolic diseases [4][7]. - The company targets high unmet needs and large market opportunities with non-opioid therapies, aiming to improve patient outcomes [4]. Product Portfolio - Scilex's commercial products include: - ZTlido (lidocaine topical system) 1.8%, approved by the FDA for neuropathic pain relief associated with postherpetic neuralgia [4]. - ELYXYB, the only FDA-approved ready-to-use oral solution for acute migraine treatment in adults [4]. - Gloperba, the first liquid oral version of colchicine for the prophylaxis of painful gout flares in adults [4]. - The company has three product candidates in development: - SP-102 (SEMDEXA™), a viscous gel formulation for epidural injections to treat lumbosacral radicular pain, which has completed a Phase 3 study and received Fast Track status from the FDA [5]. - SP-103, a next-generation lidocaine topical system for acute pain, which has completed a Phase 2 trial and also received Fast Track status [6]. - SP-104, a novel low-dose delayed-release naltrexone for fibromyalgia treatment [6]. Legal Counsel Appointment - Kasowitz LLP will provide advice on complex commercial litigation, patent litigation, intellectual property enforcement, and licensing matters [2]. - Marc Kasowitz is recognized for his expertise in high-stakes intellectual property and complex commercial litigation, enhancing Scilex's legal strategy [3].

SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / January 2, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it received notice from the U.S. Food and Drug Administration's Center for Veterinary Medicine (CVM) on January 1, 2026 that the company has been awarded a $240,000 grant. Canalevia-CA1 is currently conditionally approved for chemotherapy-induced diarrhea (CID) in dogs. ...

NEW YORK, Jan. 2, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Telix Pharmaceuticals Ltd. ("Telix Pharmaceuticals Ltd." or the "Company") (NASDAQ: TLX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Telix Pharmaceuticals Ltd. investors who were adversely affected by alleged securities fraud between February 21, 2025 and August 28, 2025. Follow the link below to get more information and be contacted by a member of our team: https: ...

Group 1: Market Overview - As of January 2, 2026, two stocks in the health care sector are signaling potential warnings for momentum-focused investors [1] - The Relative Strength Index (RSI) is a key momentum indicator that helps traders assess stock performance by comparing price strength on up days versus down days [2] Group 2: Company Analysis - Teva Pharmaceutical Industries Ltd - Teva Pharmaceutical's long-term issuer credit rating was upgraded by S&P Global Ratings from 'BB' to 'BB+' with a stable outlook [6] - Teva's stock has increased approximately 16% over the past month, reaching a 52-week high of $31.99 [6] - The current RSI value for Teva is 71.6, indicating it may be overbought [6] - Teva's shares closed at $31.21, reflecting a slight decline of 0.4% [6] - Teva has a momentum score of 92.72 and a value score of 27.43 [6] Group 3: Company Analysis - Exact Sciences Corp - Exact Sciences was involved in a significant acquisition by Abbott Laboratories, which agreed to purchase the company for $105 per common share, totaling an equity value of approximately $21 billion [6] - Exact Sciences' stock has gained around 7% over the past month, with a 52-week high of $102.00 [6] - The RSI value for Exact Sciences is 77.8, suggesting it is also potentially overbought [6] - Exact Sciences' shares closed at $101.56, down 0.3% [6]

Core Insights - AbbVie has established a significant neuroscience franchise, initially supported by Botox Therapeutic and Vraylar, now expanded to include Ubrelvy, Qulipta, and Vyalev [1][4] Sales Performance - Neuroscience segment sales represented over 17% of AbbVie's total revenues in the first nine months of 2025, driven by strong sales growth in Botox Therapeutic, Vraylar, Qulipta, and Ubrelvy, all showing double-digit increases year-over-year [2][9] - Vyalev generated $299 million in sales during the same period, contributing to the overall growth despite declines in older therapies like Duodopa [2] Future Projections - AbbVie anticipates neuroscience sales to reach $10.7 billion by the end of 2025, indicating a 19% growth compared to 2024 [3][9] - The company is preparing to enhance its neuroscience portfolio with new therapies, including tavapadon, a potential oral treatment for Parkinson's disease, which could launch later this year [4] Pipeline Expansion - AbbVie is heavily investing in expanding its neuroscience pipeline, including the acquisition of Gilgamesh Pharmaceuticals' bretisilocin, aimed at treating major depressive disorder [5] Competitive Landscape - Key competitors in the neuroscience space include Biogen and Johnson & Johnson, both diversifying their portfolios with novel therapies [6][7] Valuation and Market Performance - AbbVie shares have outperformed the industry over the past year, trading at a P/E ratio of 21.41, above the industry average of 19.26 and its five-year mean of 13.53 [8][11] - The Zacks Consensus Estimate for AbbVie's 2025 EPS remains steady at $10.64, with a slight increase for 2026 from $14.40 to $14.42 [13]

Key TakeawaysUS pre-market indices and "Magnificent Seven" tech stocks are showing strong gains, with the Nasdaq 100 futures up 1%. This positive sentiment extends across the broader market, with S&P 500 futures also rising by 0.6% and Dow Jones futures by 0.51%.Ironwood Pharmaceuticals (IRWD) surged 18% in pre-market trading following the release of stellar fiscal year 2026 revenue guidance. The company anticipates total revenue between $450 million and $475 million for FY26, alongside an adjusted EBITDA e ...

Toronto, Ontario--(Newsfile Corp. - January 2, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher") today announced that CEO Fabio Chianelli has published a letter to shareholders.Dear Shareholders,With 2025 complete, I want to thank you for your continued support of PharmaTher. This past year marked a shift from ambitious development to concrete validation, setting the stage for what I believe will be a value-unlocking year ahead.PharmaTher's strategy is clear: to ac ...

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2026 of $1.30 per share on the company's common stock. The dividend is payable on March 10, 2026 to shareholders of record at the close of business on February 24, 2026. The ex-dividend date is February 24, 2026. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare in. ...

Core Insights - Alpha Wealth Insiders Fund reported a return of 4.96% in September 2025, with year-to-date returns reaching 21.37%, outperforming the S&P 500's September return of 3.65% and year-to-date return of 14.83% [1] Group 1: Company Performance - Eli Lilly and Company (NYSE: LLY) achieved a one-month return of 5.93% and a 52-week gain of 38.12%, closing at $1,074.68 per share with a market capitalization of $963.404 billion on December 31, 2025 [2] - Eli Lilly's revenue grew by 54% in Q3 2025 compared to the same period last year, indicating strong business performance [4] Group 2: Business Overview - Eli Lilly is recognized as a pharmaceutical powerhouse, known for its products like Mounjaro and Zepbound in weight-loss and diabetes treatment, as well as its cancer and immunology drugs, and a promising Alzheimer's pipeline [3] - The company's stock is benefiting from the GLP-1 wave, contributing to significant growth and market-cap dominance [3] Group 3: Market Position - Eli Lilly ranks 21st among the 30 most popular stocks among hedge funds, with 114 hedge fund portfolios holding its stock at the end of Q3 2025, a slight decrease from 119 in the previous quarter [4]

Group 1 - SGA's U.S. Large Cap Growth Strategy reported a portfolio return of -1.3% (Gross) and -1.4% (Net) in Q3, underperforming the Russell 1000 Growth Index which returned 10.5% and the S&P 500 Index which returned 8.1% [1] - The investment objective of SGA is to invest in high-quality growth businesses expected to achieve consistent mid-teens earnings growth, along with stable revenue and cash flow [1] - In Q3, lower-quality stocks and cyclical industries outperformed, adversely affecting SGA's investment style [1] Group 2 - Novo Nordisk A/S (NYSE:NVO) was highlighted in SGA's third-quarter investor letter, with a one-month return of 6.02% and a 52-week loss of 41.86% [2] - As of December 31, 2025, Novo Nordisk A/S stock closed at $50.88 per share, with a market capitalization of $226.084 billion [2] - SGA liquidated its position in Novo Nordisk A/S in July and initiated a position in Nike due to concerns regarding Novo Nordisk's long-term growth potential [3]